163 related articles for article (PubMed ID: 38275392)
1. Preliminary Study of the Relationship between Osteopontin and Relapsed Hodgkin's Lymphoma.
De Re V; Lopci E; Brisotto G; Elia C; Mussolin L; Mascarin M; d'Amore ESG; Aieop The Hodgkin's Lymphoma Research Network
Biomedicines; 2023 Dec; 12(1):. PubMed ID: 38275392
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.
Devillier R; Coso D; Castagna L; Brenot Rossi I; Anastasia A; Chiti A; Ivanov V; Schiano JM; Santoro A; Chabannon C; Balzarotti M; Blaise D; Bouabdallah R
Haematologica; 2012 Jul; 97(7):1073-9. PubMed ID: 22271893
[TBL] [Abstract][Full Text] [Related]
3. Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin's or Non-Hodgkin's Lymphoma?
Çetin G; Çıkrıkçıoğlu MA; Özkan T; Karatoprak C; Ar MC; Eşkazan AE; Ayer M; Cerit A; Gözübenli K; Uysal BB; Erdem S; Ergül N; Tatar G; Çermik TF
Turk J Haematol; 2015 Sep; 32(3):213-9. PubMed ID: 25912844
[TBL] [Abstract][Full Text] [Related]
4. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
5. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
[TBL] [Abstract][Full Text] [Related]
6. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results.
Rigacci L; Castagnoli A; Dini C; Carpaneto A; Matteini M; Alterini R; Carrai V; Nassi L; Bernardi F; Pieroni C; Bosi A
Oncol Rep; 2005 Nov; 14(5):1209-14. PubMed ID: 16211287
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic evaluation value of (18)F-FDG PET-CT in Hodgkin's lymphoma after treatment].
Wan H; Liu P; Liang Y; Jiang SY; Lyu L; Zhang ZW; Wu N; Liu Y
Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1275-1281. PubMed ID: 34915636
[No Abstract] [Full Text] [Related]
8. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of SPP1/osteopontin expression as predictor of recurrence in tamoxifen treated breast cancer.
Göthlin Eremo A; Lagergren K; Othman L; Montgomery S; Andersson G; Tina E
Sci Rep; 2020 Jan; 10(1):1451. PubMed ID: 31996744
[TBL] [Abstract][Full Text] [Related]
10. Semiquantitative analysis of interim
Ribeiro T; Marques A; Ferreira G; Castro C; Tavares M; Espírito-Santo A; Moreira C; Mariz J
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(5):281-286. PubMed ID: 34425968
[TBL] [Abstract][Full Text] [Related]
11. FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial.
Lopci E; Mascarin M; Piccardo A; Castello A; Elia C; Guerra L; Borsatti E; Sala A; Todesco A; Zucchetta P; Farruggia P; Cistaro A; Buffardi S; Bertolini P; Bianchi M; Moleti ML; Bunkheila F; Indolfi P; Fagioli F; Garaventa A; Burnelli R;
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):97-106. PubMed ID: 30219963
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease.
Lang O; Bihl H; Hültenschmidt B; Sautter-Bihl ML
Strahlenther Onkol; 2001 Mar; 177(3):138-44. PubMed ID: 11285771
[TBL] [Abstract][Full Text] [Related]
13. [The prognostic significance of peripheral lymphocyte/monocyte ratio and PET-2 evaluation in adult Hodgkin's lymphoma].
Jia T; Zhu HY; Wang L; Liang JH; Cao L; Xia Y; Wu JZ; Wu W; Fan L; Li JY; Xu W
Zhonghua Xue Ye Xue Za Zhi; 2019 May; 40(5):372-377. PubMed ID: 31207700
[No Abstract] [Full Text] [Related]
14. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
Ngeow JYY; Quek RHH; Ng DCE; Hee SW; Tao M; Lim LC; Tan YH; Lim ST
Ann Oncol; 2009 Sep; 20(9):1543-1547. PubMed ID: 19474116
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin (OPN)/Secreted Phosphoprotein 1 (SPP1) Binds Integrins to Activate Transport of Ions Across the Porcine Placenta.
Wu G; Li X; Seo H; McLendon BA; Kramer AC; Bazer FW; Johnson GA
Front Biosci (Landmark Ed); 2022 Apr; 27(4):117. PubMed ID: 35468676
[TBL] [Abstract][Full Text] [Related]
16. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Moskowitz AJ; Schöder H; Yahalom J; McCall SJ; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz S; Kobos R; Kumar A; Matasar M; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Shukla N; Steinherz P; Straus D; Trippett T; Younes A; Zelenetz A; Moskowitz CH
Lancet Oncol; 2015 Mar; 16(3):284-92. PubMed ID: 25683846
[TBL] [Abstract][Full Text] [Related]
17.
Eisazadeh R; Mirshahvalad SA
Clin Imaging; 2022 Dec; 92():25-31. PubMed ID: 36179394
[TBL] [Abstract][Full Text] [Related]
18. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study.
Zaucha JM; Malkowski B; Chauvie S; Subocz E; Tajer J; Kulikowski W; Fijolek-Warszewska A; Biggi A; Fallanca F; Kobylecka M; Dziuk M; Woszczyk D; Rybka J; Kroll-Balcerzak R; Bergesio F; Romanowicz A; Chamier-Cieminska A; Kurczab P; Giza A; Lesniewski-Kmak K; Zaucha R; Swietlik D; Wróbel T; Knopinska-Posluszny W; Walewski J; Gallamini A
Ann Oncol; 2017 Dec; 28(12):3051-3057. PubMed ID: 28950332
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-Hodgkin's lymphoma.
Manohar K; Mittal BR; Bhattacharya A; Malhotra P; Varma S
Nucl Med Commun; 2012 Sep; 33(9):974-81. PubMed ID: 22811258
[TBL] [Abstract][Full Text] [Related]
20. Osteopontin: its potential role in cancer of children and young adults.
Karpinsky G; Fatyga A; Krawczyk MA; Chamera M; Sande N; Szmyd D; Izycka-Swieszewska E; Bien E
Biomark Med; 2017 Apr; 11(4):389-402. PubMed ID: 28326824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]